The *bcr-abl* rearrangement in T-lineage ALL has been rarely described. In the last three years we studied all new patients with ALL at diagnosis by cytogenetic and molecular analysis. Three out of eleven T-lineage ALL patients presented the rearrangement and only one was Philadelphia positive.

The Philadelphia (Ph) chromosome, t(9;22) (q34;q11), is present in more than 95% of patients with chronic myelogenous leukemia (CML) and in 15-25% of adults with acute B-lineage lymphoblastic leukemia (ALL). In T-lineage ALL it has rarely been reported and singular cases of T-lineage adult ALL carrying the *bcr-abl* rearrangement have been recently described. *bcr-abl* rearrangement in T-lineage ALL is thus a rare event and the clinical relevance of this translocation is currently unknown.

In the last three years we studied 25 new consecutive cases of ALL (14 B-lineage and 11 T-lineage). We present here the clinical, immunologic, cytogenetic and molecular features of three out of the eleven T-lineage ALL patients presenting *bcr-abl* rearrangement at diagnosis.

**Patient #1.** A 15-year-old male was referred with a recent history of cough and fatigue. He was treated with daunomycin, vincristine, asparaginase, and prednisone and obtained a complete remission. He relapsed 7 months later, did not obtained a second remission and died 4 months later.

**Patient #2.** A 32-year-old male was admitted with acute leukemia. He was treated with idarubicin, cytarabine, vincristine and prednisone and obtained complete remission. He was later submitted to allogeneic peripheral blood transplantation from his HLA-identical sister while in first CR. The patient developed acute but not chronic GVHD. He relapsed 18 months later. He is actually in second CR after reinduction treatment.

**Patient #3.** A 47-year-old male was admitted with acute pericarditis. The chest X-ray and chest CT scan showed massive mediastinal enlargement and pleural and pericardial effusion. Blood counts were normal, but differential counts showed 20% blast cells. Bone marrow aspiration revealed 50% blast cells with cerebrocortex nucleus. Pleural fluid contained 117.0 x 10^9/L blast cells. The patient was treated with daunoblastin, vincristine, asparaginase and prednisone and obtained complete remission. He was submitted to autologous peripheral staminal cell transplantation, but died of adult respiratory distress syndrome two weeks later.

Clinical and biological data are shown in Table 1. *bcr-abl* transcript was detected by RT-PCR and the rearrangements occur in all patients within the 5.8-kb M-bcr region associated with P210 *bcr-abl* expression; monoclonal rearrangement of the TCRg gene, but not of the IGH locus was also detected by PCR (Figure 1).

Ph+ CML is known to arise in a multipotent hematopoietic stem cell. This is also shown by the fact that Ph translocation and/or *bcr-abl* expression can be simultaneously found in cells of myeloid and lymphoid lineage. Occasional reports of Ph+ T-cell blast crisis of CML provide evidence that T-cell precursors can be involved in Ph+ leukemic transformation. Single cases of T-lineage ALL with Ph translocation or *bcr-abl* rearrangement have also been reported.

The characteristics of our three *bcr-abl* T-ALL cases are indistinguishable from other T-lineage ALL. Two presented with mediastinal enlargement and one patient had intermediate characteristics between T-ALL and T mediastinal lymphoblastic lymphoma.

We do not know whether the presence of *bcr-abl* gene rearrangement makes the prognosis of T-lineage ALL worse, but two out of three patients had bad prognosis characteristics such as early B phenotype,
Scientific letters

high WBC count and extranodal involvement. The presence of bcr-abl rearrangement in T-ALL is a rare event. Our cases are probably an occasional series. Nevertheless the real incidence and the significance of bcr-abl rearrangement in T-lineage ALL is not known. We think that further studies on the molecular biology of T-ALL could be useful.

Funding
This work is in part supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and by a grant from the Associazione Italiana contro le Leucemie (AIL).

Correspondence
Francesco Fabbiano, MD, Divisione di Ematologia, Azienda Ospedaliera “V. Cervello”; via Trabucco 180; 90146 Palermo, Italy. Phone: international +39-091-6802962 • Fax: international +39-091-6883145 • E-mail: francesco.fabbiano@schering-pl.it

AIDS-related non-Hodgkin's lymphomas from an Italian area

ROBERTO FERRETTI, ROBERTO LUZZATI, DINO VENERI*, PIERANGELO ROVERE*, MAURIZIO SOLBIATI, ERCOLE CONCIA

Institute of Immunology and Infectious Diseases; *Department of Hematology, University of Verona, Italy; **Section of Infectious Diseases, Hospital of Legnago (Verona), Italy

In a retrospective study, 42 (7.7%) of 545 patients with AIDS from a single area of Italy had non-Hodgkin’s lymphoma (28 systemic and 14 primary central nervous system lymphomas). The improved outcome and survival of treated patients outlines the clinical benefit of antineoplastic treatment in selected cases.

It has been widely recognized that patients with HIV-related immunosuppression are at increased risk of developing non-Hodgkin’s lymphomas (NHL) that include systemic, primary central nervous system (P-CNS-L) and body cavity-based lymphomas.1 At present in Italy the incidence of NHL is 3.5% according to the Centro Operativo AIDS.2 However, this figure represents only the first AIDS-defining condition, potentially missing lymphomas occurring at a later stage.

We have retrospectively evaluated the epidemiological and clinical characteristics of 42 cases (7.7%) of NHL among 545 patients with AIDS admitted to the Infectious Diseases Departments of the Verona area up to June 1997. Baseline characteristics of patients are shown in Table 1. Systemic-NHL were of B-cell type and classified as follows: 18 large cell, 4

References